Pharmaceutical Technology Europe-04-01-2009

The number of biotechnology-based human therapeutic products in the late-stage pipeline along with the average cost to commercialize a biotech product has been steadily increasing with time. In addition, the biotech industry is facing unprecedented challenges of a sagging global economy and rising regulatory expectations. Companies have to continue to evolve their approaches to be more efficient with respect to time, resources and cost. This article describes some of the technologies that can help optimize time and cost of biopharmaecutical manufacturing.

Despite the market downturn and financial meltdown, private equity investors are lining up for pharmaceutical services businesses.

Operational excellence awaits, but only if you can implement PAT successfully.

An expert on diffraction systems offers insight on particle size specifications and analysis.

The formation of a partnership, whether personal or professional, is risky business.

Even small amounts of amorphous materials can have a significant effect on the drug product. Are gravimetric vapour sorption techniques an effective solution to characterize amorphous materials?

Steps companies can take to help safeguard patients and the pharma supply chain.